SCHEMBL10102398

SCHEMBL10102398

COc1ccc2c3c(c4c(c2c1)OC(c1ccccc1)(c1ccc(N2CCOCC2)cc1)C=C4)C1(CCCCCCC1)c1ccccc1-3

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.34
TSHR P16473 2/20 0.34
HSD17B10 Q99714 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPK1 P28482 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
ATM Q13315 4/20 0.33
AKT1 P31749 1/20 0.32
ADAM17 P78536 1/20 0.32
ALDH1A1 P00352 4/20 0.32
KDM4E B2RXH2 3/20 0.32
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
STK10 O94804 1/20 0.31
SLK Q9H2G2 1/20 0.31
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26032649 0.98 AKT1 (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL10102285 0.95 MAPT (0.33) MAPT
SCHEMBL15763601 0.94 MAPT (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL27393177 0.93 AKT1 (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL21636950 0.92 CYP3A4 (0.35) MAPTKMT2AATMAKT1ALDH1A1
SCHEMBL25954005 0.92 POLB (0.32) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL24678603 0.92 ATM (0.33) MAPTTSHRHSD17B10MAPK1KMT2A
SCHEMBL22864324 0.92 ATM (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL20369879 0.90 MAPT (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1
SCHEMBL676103 0.90 MAPT (0.34) MAPTTSHRHSD17B10SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 MAPT 3134/4885TSHR 354/4885HSD17B10 1470/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 MAPT 4740/4885TSHR 330/4885HSD17B10 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.